Zydus Recalls Lansoprazole Tablets for Failed Dissolution Specifications
Zydus Pharmaceuticals is recalling 22,848 cartons of Lansoprazole 30 mg tablets nationwide because they failed to meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II due to failed dissolution specifications, which is a quality control issue that may lead to temporary or medically reversible adverse health consequences, fitting the 'Moderate' severity criteria for low-risk contamination or voluntary precautionary recalls without reported injuries.
Plain-English summary
Zydus Pharmaceuticals (USA) Inc. is recalling 22,848 cartons of Lansoprazole Delayed-Release Orally Disintegrating Tablets, 30 mg. The product is distributed nationwide and is available in 100-tablet blister packs (10 x 10 unit-dose). The recall is due to the tablets failing to meet dissolution specifications.
The affected lots are M900412 (December 2020), M904772 (February 2021), and M915745 (October 2021). The product is manufactured by Cadila Healthcare Ltd. in Ahmedabad, India, and distributed by Zydus Pharmaceuticals USA Inc. in Pennington, NJ. The NDC for the recalled product is 68382-772-77.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance. The FDA classifies this recall as Class II, indicating a situation in which use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- LANSOPRAZOLE (LANSOPRAZOLE)
- Brand
- LANSOPRAZOLE
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 22,848
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- M900412 December 2020 M904772 February 2021 M915745 October 2021
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Zydus Pharmaceuticals (USA) Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · LANSOPRAZOLE
- HighLansoprazole tablets recalled nationwide due to failed dissolution specifications
FDA (Drugs) · 2022-08-03
- High
- HighLansoprazole Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2022-05-11
- HighLansoprazole Capsules Recalled for Failed Dissolution in Stability Testing
FDA (Drugs) · 2022-04-06
- ModerateLansoprazole Delayed-Release Capsules Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-04-06
Same manufacturer · Zydus Pharmaceuticals (USA) Inc
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereErythromycin 500 mg Tablets Recalled for Impurity Above Limits
FDA (Drugs) · 2026-05-27
- HighIcosapent ethyl capsules recalled after active ingredient oxidized inside capsule
FDA (Drugs) · 2026-03-18
- HighIcosapent ethyl capsules recalled as subpotent after capsule contents leaked
FDA (Drugs) · 2026-01-28
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22